hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00082758 |
|
Recruitment Status :
Completed
First Posted : May 19, 2004
Results First Posted : January 16, 2014
Last Update Posted : February 12, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing.
PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurrent or refractory neuroblastoma.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Neuroblastoma | Biological: hu14.18-Interleukin-2 fusion protein | Phase 2 |
OBJECTIVES:
- Determine the response rate in children with recurrent or refractory neuroblastoma treated with hu14.18-interleukin-2 (hu14.18-IL2) fusion protein.
- Determine the adverse events of this drug in these patients.
- Determine the immunologic activation in patients treated with this drug.
- Determine the induction of anti-hu14.18-IL2 antibody in patients treated with this drug.
- Correlate antitumor response with measurements of toxicity, immune activation, and anti-hu14.18-IL2 antibody activity in patients treated with this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to measurable/evaluable disease (measurable by standard radiographic criteria vs evaluable by MIBG (meta-iodobenzylguanidine) scanning and/or bone marrow histology vs disease identified and quantified by bone marrow immunohistochemistry).
For standard radiographic criteria this study will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute. Complete Response (CR) - Disappearance of all target lesions. No evidence of tumor at any site (chest, abdomen, liver, bone, bone marrow, nodes, etc). Very Good Partial Response (VGPR) - Greater than 90% decrease of the disease measurement for CT/MRI target lesions, taking as reference the disease measurement done to confirm measurable disease in target lesions at study entry; all pre-existing bone lesions with CR by MIBG; MIBG scan can be SD or CR in soft tissue lesions corresponding to lesions on CT/MRI. Partial Response (PR) - At least a 30% decrease in the disease measurement for CT/MRI target lesions, taking as reference the disease measurement done to confirm measurable disease in target lesions at study entry. Progressive Disease (PD) - Any one of the following: a) At least a 20% increase in the disease measurement for CT/MRI target lesions, taking as reference the smallest disease measurement recorded since the start of treatment. b) Appearance of one or more new lesions or new sites of tumor. c) PD as defined above for either bone marrow or MIBG lesions.
Stable disease (SD) - The patient will be classified as stable disease for overall response if there is stable disease by either CT/MRI lesion, bone marrow, or MIBG criteria. No new lesions; no new sites of disease.
Patients will be enrolled in 3 strata, and evaluated for antitumor response following 2 monthly courses (treatment on Days 1-3, followed by 25 days of observation,). Patients with progressive disease will be taken off protocol therapy. Patients with stabilization or regression of disease will be eligible to receive 2 more monthly courses of treatment. Additional treatment following course 4 will be allowed for patients showing a continued clinical response, up to a maximum of 10 courses of treatment.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 40-60 patients (20 for strata 1 and 2 and 0-20 for stratum 3) will be accrued for this study within 2 years.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 39 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Study Of hu14.18-IL2 In Children With Recurrent Or Refractory Neuroblastoma |
| Study Start Date : | August 2005 |
| Actual Primary Completion Date : | February 2008 |
| Actual Study Completion Date : | May 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Disease Measurable by Standard Criteria(hu14.18-interleukin-2)
Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute. hu14.18-Interleukin-2 fusion protein : Given IV |
Biological: hu14.18-Interleukin-2 fusion protein
Given IV
Other Names:
|
|
Experimental: Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)
Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology. hu14.18-Interleukin-2 fusion protein : Given IV |
Biological: hu14.18-Interleukin-2 fusion protein
Given IV
Other Names:
|
|
Experimental: Disease Identified by BM Immunohistochemistry Only
Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (>5 neuroblastoma cells per 1,000,000 nucleated marrow cells). hu14.18-Interleukin-2 fusion protein : Given IV |
Biological: hu14.18-Interleukin-2 fusion protein
Given IV
Other Names:
|
- Number of Responders (Response Rate) [ Time Frame: Up to 30 weeks ]Response rate to hu14.18-Interleukin-2 in 3 separate strata of patients with recurrent or refractory neuroblastoma. Patients will have radiologic (CT/MRI) tumor and urine homovanillic acid (HVA)/vanillylmandelic acid (VMA) measurements. Patients with prior marrow involvement will have marrow assessments. Patients with MIBG+ (iodine-131-meta-iodobenzylguanidine) prior disease will have MIBG scans performed. For CT/MRI lesions, measureable disease is measured by the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute. RECIST (v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 21 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Histologically confirmed neuroblastoma
- Relapsed or refractory to conventional therapy
-
Measurable or evaluable disease documented by 1 of the following criteria:
- Clinical
- Radiographic
- Histologic
- MIBG (meta-iodobenzylguanidine) scanning
- Immunocytochemistry
- No symptomatic pleural effusions or ascites requiring constant or intermittent drainage
- No clinical or radiological evidence of central nervous system (CNS) disease
PATIENT CHARACTERISTICS:
Age
- 21 and under
Performance status
- Karnofsky 50-100% (> 16 years of age)
- Lansky 50-100% (≤ 16 years of age)
Life expectancy
- At least 8 weeks
Hematopoietic
- Absolute neutrophil count > 1,000/mm^3
-
Platelet count ≥ 75,000/mm^3*
- Must not be refractory to platelet transfusions
- Hemoglobin ≥ 9.0 g/dL* NOTE: *Transfusion allowed if patient is known to have a history of bone marrow involvement with tumor
Hepatic
- Alanine transaminase (ALT) < 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 1.5 times ULN
- Hepatitis B surface antigen negative
Renal
-
Creatinine adjusted according to age as follows:
- No greater than 0.4 mg/dL (≤ 5 months)
- No greater than 0.5 mg/dL (6 months -11 months)
- No greater than 0.6 mg/dL (1 year-23 months)
- No greater than 0.8 mg/dL (2 years-5 years)
- No greater than 1.0 mg/dL (6 years-9 years)
- No greater than 1.2 mg/dL (10 years-12 years)
- No greater than 1.4 mg/dL (13 years and over [female])
- No greater than 1.5 mg/dL (13 years to 15 years [male])
- No greater than 1.7 mg/dL (16 years and over [male]) OR
- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
Cardiovascular
- Shortening fraction ≥ 27% by echocardiogram OR
- Ejection fraction ≥ 50% by Multi Gated Acquisition Scan (MUGA)
- No symptomatic congestive heart failure
- No uncontrolled cardiac rhythm disturbance
Pulmonary
- Pulse oximetry > 94% on room air
- Forced vital capacity (FVC) > 80%
- Forced expiratory volume (FEV_1) > 80%
- No abnormal respiratory function
- No dyspnea at rest
- No exercise intolerance
- No prior history of ventilator support related to lung injury (e.g., pneumonia, hemorrhagic pneumonitis, or capillary leakage)
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No active uncontrolled infection
- No active uncontrolled peptic ulcer
- No objective peripheral neuropathy ≥ grade 2
- No significant psychiatric disabilities
- No seizure disorders requiring antiseizure medications
- No other concurrent significant illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Recovered from prior immunotherapy
- Prior in vivo monoclonal antibodies for biologic therapy or tumor imaging allowed provided there is documented absence of detectable antibody to hu14.18 by serology
-
More than 28 days since prior autologous stem cell transplantation
- Prior autologous marrow or stem cell infusion using monoclonal antibody-purged specimens allowed
- More than 1 week since prior growth factors
- At least 7 days since prior nonmyelosuppressive biologic agents
- No prior allogeneic bone marrow or stem cell transplantation
- No concurrent immunomodulating agents
- No concurrent growth factors
Chemotherapy
- More than 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
- No concurrent anticancer chemotherapy
Endocrine therapy
-
No concurrent corticosteroids except 100 mg or less of hydrocortisone (or equivalent) as premedication for blood transfusion or treatment for transfusion reaction
- No other use of systemic steroids
Radiotherapy
- Recovered from prior radiotherapy
- At least 2 weeks since prior local palliative radiotherapy (small port)
- At least 6 months since prior craniospinal radiotherapy
- At least 6 months since prior total body irradiation
- At least 6 months since prior radiotherapy to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- Concurrent radiotherapy to localized painful lesions allowed provided at least 1 measurable or evaluable lesion is not irradiated
Surgery
- More than 2 weeks since prior major surgery (e.g., laparotomy or thoracotomy)
- No prior organ allografts
Other
- No concurrent immunosuppressive drugs
- No other concurrent myelosuppressive antineoplastic drugs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00082758
Show 81 study locations
| Study Chair: | Paul M Sondel, MD, PhD | University of Wisconsin, Madison | |
| Study Chair: | Suzanne Shusterman, MD | Dana-Farber Cancer Institute |
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00082758 |
| Other Study ID Numbers: |
ANBL0322 CDR0000360723 ( Other Identifier: Clinical Trials.gov ) COG-ANBL0322 ( Other Identifier: Children's Oncology Group ) NCI-2012-02583 ( Other Identifier: NCI ) |
| First Posted: | May 19, 2004 Key Record Dates |
| Results First Posted: | January 16, 2014 |
| Last Update Posted: | February 12, 2015 |
| Last Verified: | January 2015 |
|
recurrent neuroblastoma |
|
Neuroblastoma Neuroectodermal Tumors, Primitive, Peripheral Neuroectodermal Tumors, Primitive Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms, Nerve Tissue Interleukin-2 Denileukin diftitox Antineoplastic Agents Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |